Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We historically created next generation immunotherapies using breakthrough de novo protein design technology. In December 2023, the previously announced merger between Neurogene Inc and Neoleukin Therapeutics (NGNE) was completed. Neurogene is a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases. For more information about the Neurogene, please visit www.neurogene.com, @NeurogeneInc on X (formerly Twitter) or @Neurogene Inc on LinkedIn.
